Chapter PDF
References
National Institute of Allergy and Infectious Diseases, National Institutes of Health (2002) The Jordan report: Accelerated development of vaccines. The Institute, Bethesda
Batson A, Glass S, Whitehead P (2004) Vaccine economics: from candidates to commercialized products in the developing world. In: MM Levine, J Kaper, R Rappouli, M Liu, M Good (eds): New generation vaccines. Marcel Dekker, Inc., New York, 57–74
Clemens J, Naficy A, Rao M, Koo H (2004) Long-term evaluation of vaccine protection:methodological issues for phase III and IV studies. In: MM Levine, J Kaper, R Rappouli, M Liu, M Good (eds): New generation vaccines. Marcel Dekker, Inc., New York, 29–48
Wilson GS (1967) The hazards of immunization. Athlone Press, London
Kapikian A, Mitchell RH, Chanock RM, Shevdoff RA, Stewart CE (1969) An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection of children previously vaccinated with an RS virus vaccine. Am J Epidemiol 89: 422–434
Rauh LW, Schmitdt R (1965) Measles immunization with killed virus vaccine, serum antibody titers and experience with exposure to measles epidemic. Am J Dis Child 109: 232–237
Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, Zanardi LR, Setia S, Fair E, Le Baron CW et al (2001) Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344: 564–572
Kramarz P, France EK, Destefano F, Black SB, Shinefield H, Ward JI, Chang EJ, Chen RT, Shatin D, Hill J et al (2001) Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis 20: 410–416
Levine MM, Kaper JB, Herrington D, Ketley J, Losonsky G, Tacket C, Tall B, Cryz S (1988) Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 332: 467–470
Simanjuntak C, O’Hanley P, Punjabi N, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Budiarsno A, Rifai A et al (1993) The safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 25–59 month old Indonesian children. J Infect Dis 168: 1169–1176
Miller FG, Grady C (2001) The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis 33: 1028–1033
Rosenbaurm J, Sepkowitz K (2002) Infectious disease experimentation involving human volunteers. Clin Infect Dis 34: 963–971
Tacket, Kotloff K, Rennels M (2004) Initial clinical evaluation of new vaccine candidates: investigators’ perspective of phase I and phase II clinical trials of safety, immunogenicity, and preliminary efficacy. In: MM Levine, J Kaper, R Rappouli, M Liu, M Good (eds): New generation vaccines. New York: Marcel Dekker, Inc., New York, 19–28
Clemens J, Brenner R, Rao M, Tafari N, Lowe C (1996) Evaluating new vaccines for developing countries: efficacy or effectiveness? J Am Med Assoc 275: 390–397
Kallings L, Olin P, Storsaeter J (1988) Protective effect of two acellular pertussis vaccines in a double-blind, placebo-controlled trial. Lakartidningen 85: 1994–1996
Patriarca P, Wright PF, John TJ (1991) Factors affecting the immunogenicity of oral polio vaccine in developing countries: a review. Rev Infect Dis 13: 926–939
Hanlon P (1987) Trial of an attenuated bovine rotavirus vaccine (RIT4237) in Gambian infants. Lancet 1: 1342–1345
Ward J, Brenneman G, Letson G, Heyward W (1990) Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaskan Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 323: 1393–1401
Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM et al (2000) Efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemicarea. Vaccine 18: 2399–2410
Watt J, Levine O, Santosham M (2003) Global reduction of Hib disease: what are the next steps? J Pediatr 143(6 Suppl): S163–S187
Abram IS (1995) Designing HIV vaccines for developing countries. Harv AIDS Rev Fall: 17–19
Glass R, Bresee J, Parashar U, Jiang B, Gentsch J (2004) The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 363: 1547–1550
Su-Arehawaratana P, Singharaj P, Taylor D, Hoge C, Trofa A, Kuvanont K, Migasena S, Pitisuttitham P, Lim YL, Losonsky G et al (1992) Safety and immunogenicity of different immunization regimens of CVD103-HgR live oral choleravaccine in soldiers and civilians in Thailand. J Infect Dis 165: 1042–1048
Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA et al (1999) Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-Hg-R in preventing cholera following challenge with Vibrio cholerae 01 El Tor Inaba three months after vaccination. Infect Immun 67: 6341–6345
Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, Cortese M, Sack D, Hill J, Newcomer W et al (1991) The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseriae meningitidis outer-membrane protein complex. N Engl J Med 324: 1767–1772
Black S, Shinefield H, Fireman B, Hiatt R, Polen M, Vittinghoff (1991) Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HibOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 10: 97–104
Goldenthal K, Falk LA, Ball L, Geber A (2001) Prelicensure evaluation of combination vaccines. Clin Infect Dis 33(Suppl 4): S267–S273
International Conference on Harmonisation Expert Working Group (1996) International Conference on Harmonisation Guideline for Good Clinical Practice. E6. The Conference, Geneva
Greco M (2001) The future of vaccines: an industrial perspective. Vaccine 20(Suppl 1): S101–S103
The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1979) The Belmont report: ethical principles and guidelines for the protection of human subjects of research. The Commission, Bethesda, 1–8
Angel M (1997) The ethics of clinical research in the Third World. N Engl J Med 337: 847–849
Shapiro HT, Meslin EM (2001) Ethical issues in the design and conduct of clinical trials in developing countries. N Engl J Med 345: 139–142
Varmus H, Satcher D (1997) Ethical complexities of conducting research in developing countries. N Engl J Med 337: 1003–1005
Weijer C (2000) The future of research into rotavirus vaccine. Br Med J 321: 525–526
World Medical Association (2002) Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. The Association. Available from: URL: http://www.wma.net/e/policy/b3.htm
Joint United Nations Programme on HIV/AIDS (2000) Ethical considerations in HIV preventive vaccine research. UNAIDS, Geneva
World Medical Association (2001) When are placebo-controlled trials ethically acceptable? (Press Release: November 28, 2001) Available from: URL: http://www.wma.net/e/press/2001_1.htm
Clemens J, Keckich N, Naficy A, Rao M (1999) Public health considerations for the introduction of new vaccines against rotavirus: a case study of the rhesus rotavirus-reassortant vaccine. Epi Rev 21: 24–42
Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, Wassilak SG (1994) The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12: 542–550
Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM et al (1997) Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics 99: 765–773
Ali M, Canh DG, Clemens J, Park J-K, von Seidlein L, Thiem VD, Tho LH, Trach DD (2003) The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations. Vaccine 21: 1681–1686
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Clemens, J.D., Ochiai, R.L. (2005). Sequential stages of clinical trials and overview of issues to be considered. In: Kaufmann, S.H., Lambert, PH. (eds) The Grand Challenge for the Future. Birkhäuser Advances in Infectious Diseases BAID. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7381-4_11
Download citation
DOI: https://doi.org/10.1007/3-7643-7381-4_11
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7175-3
Online ISBN: 978-3-7643-7381-8
eBook Packages: MedicineMedicine (R0)